Animal models for the negative symptoms of schizophrenia.
about
Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophreniaTranslational Rodent Paradigms to Investigate Neuromechanisms Underlying Behaviors Relevant to Amotivation and Altered Reward Processing in SchizophreniaRemoving obstacles in neuroscience drug discovery: the future path for animal models.Effects of the phencyclidine model of schizophrenia and nicotine on total and categorized ultrasonic vocalizations in ratsDeveloping treatments for cognitive deficits in schizophrenia: the challenge of translation.Anhedonia, avolition, and anticipatory deficits: assessments in animals with relevance to the negative symptoms of schizophreniaToll-like receptor-2 deficiency induces schizophrenia-like behaviors in miceEvaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia.Animal models of schizophrenia.Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice.Deficient NRG1-ERBB signaling alters social approach: relevance to genetic mouse models of schizophrenia.Contribution of nonprimate animal models in understanding the etiology of schizophrenia.Genetic loss of D-amino acid oxidase activity reverses schizophrenia-like phenotypes in mice.Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model.NMDA receptor phosphorylation at a site affected in schizophrenia controls synaptic and behavioral plasticity.Atypical anti-schizophrenic drugs prevent changes in cortical N-methyl-D-aspartate receptors and behavior following sub-chronic phencyclidine administration in developing rat pups.Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.Progressive ratio performance following challenge with antipsychotics, amphetamine, or NMDA antagonists in adult rats treated perinatally with phencyclidine.Ambiguous-cue interpretation is biased under stress- and depression-like states in ratsNogo Receptor 1 (RTN4R) as a candidate gene for schizophrenia: analysis using human and mouse genetic approaches.GlyT-1 Inhibition Attenuates Attentional But Not Learning or Motivational Deficits of the Sp4 Hypomorphic Mouse Model Relevant to Psychiatric DisordersNeonatal stress-induced affective changes in adolescent Wistar rats: early signs of schizophrenia-like behavior.Drugs of abuse and increased risk of psychosis development.Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia.Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia.Neuroadaptations to chronic exposure to drugs of abuse: relevance to depressive symptomatology seen across psychiatric diagnostic categories.Experimental psychiatric illness and drug abuse models: from human to animal, an overviewSocial interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia.Importance of animal models in schizophrenia research.Schizophrenia: an integrative approach to modelling a complex disorder.Animal models and treatments for addiction and depression co-morbidity.Social stress, therapeutics and drug abuse: preclinical models of escalated and depressed intake.A review of the discovery, pharmacological characterization, and behavioral effects of the dopamine D2-like receptor antagonist eticlopride.Mitragyna speciosa Leaf Extract Exhibits Antipsychotic-Like Effect with the Potential to Alleviate Positive and Negative Symptoms of Psychosis in Mice.Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus.Pregenual Anterior Cingulate Gyrus Involvement in Spontaneous Social Interactions in Primates-Evidence from Behavioral, Pharmacological, Neuropsychiatric, and Neurophysiological Findings.Signaling pathways in schizophrenia: emerging targets and therapeutic strategies.Consideration of species differences in developing novel molecules as cognition enhancers.Dissecting negative symptoms in schizophrenia: opportunities for translation into new treatments.A Review of Oxytocin's Effects on the Positive, Negative, and Cognitive Domains of Schizophrenia.
P2860
Q24632939-FEA94BCD-85B2-4B27-B0DC-A9B54DFAAA24Q26801568-9AE31294-5F11-43BB-9167-EB9EF9AE2B3CQ28755229-B92ED46A-D4CC-4EB4-9795-813B9F03EEE8Q30354969-E937B9CA-76B7-4B89-9B88-14D9D1E1BFC1Q30396775-26191CA4-6345-4CE9-8BA6-5CD4EE18DEF6Q30413012-E80A6B7D-28BE-40E5-BCBC-E8166702ECB9Q30418233-C66CEF56-7B8F-4100-BCCD-71AFAA7D71D0Q30428422-11775DC8-237C-4A6B-A7FE-950F7838EF3BQ30462828-6B66077D-D170-4355-9073-52A773EC2C70Q30468504-EF018B1B-0874-450C-B10A-41443C745445Q30473698-671921D2-4555-48AF-A349-D47B0E6342A6Q30474963-BA8A7290-6311-47BF-BABD-C407C969DC9FQ30477241-8B41BE3B-17DE-4D38-9944-BA465D93019DQ30479725-AE9410DE-188A-47EB-A711-AA1B98DD5DEAQ30484119-6CEC8135-44A9-45F3-B166-E3FF1D81495EQ30486391-3123F892-680A-49E8-83C8-74C471BAD542Q30489404-7EBB7DCF-AF35-4CC6-97C5-63958259A951Q30491416-6299CC50-8613-4926-BD82-C5DD32237C28Q30498539-A13B4CCF-3880-42E6-A2B8-C8A90422B1C1Q30499718-2E0D4654-E740-434C-AEDF-D3DBEC85DB50Q30756194-E9DBC753-4625-4E30-A4EA-EF691CF4BD59Q34159072-2FC87CF7-C573-4E15-8648-FF1EB7F949CFQ34290364-453495FA-749C-4659-BAB2-7BD97580BDFBQ34660546-6E17BAB1-4DF4-4426-A281-A2093D7803A6Q34926526-9C5DF560-5E29-4B1A-8204-655701125F7EQ35164053-F28BABEB-A335-4027-BD8C-5B7710D41371Q35774481-4DFA56C4-5228-48E5-8B47-BAB8EA9525A5Q35785068-1740ED85-8194-4BF5-9A78-8ACFFF44900DQ36183254-3527A36E-6ABF-4516-AECC-426793C1BDAAQ36478249-6D641DC3-2D57-4692-BBEF-A7A479D768BFQ36797967-7D6BBE4C-550E-43D1-8D8C-C93E57BE30B6Q37267936-1A4DF92E-F963-4B7F-A965-375001244BCCQ37272767-A6D24F68-B91B-4404-8006-2AD411144745Q37475667-FB33F932-DB5D-490B-B72E-70B6F5CC20B9Q37595873-33A89C83-30E6-4C98-A622-7178489EA830Q37617443-5CE5DD77-7E3E-480F-A89B-67E6D7DA5760Q37767805-D01BF6FF-6693-4741-A72A-673609E76AE1Q38051975-36AF7EC5-4E92-46CE-B1B4-C38A9F68E324Q38291334-B86A22B6-EAED-4CD5-A89F-6E68C8D299B5Q38593718-6496A78D-99E9-453E-B7D1-21161F8365AA
P2860
Animal models for the negative symptoms of schizophrenia.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Animal models for the negative symptoms of schizophrenia.
@ast
Animal models for the negative symptoms of schizophrenia.
@en
Animal models for the negative symptoms of schizophrenia.
@nl
type
label
Animal models for the negative symptoms of schizophrenia.
@ast
Animal models for the negative symptoms of schizophrenia.
@en
Animal models for the negative symptoms of schizophrenia.
@nl
prefLabel
Animal models for the negative symptoms of schizophrenia.
@ast
Animal models for the negative symptoms of schizophrenia.
@en
Animal models for the negative symptoms of schizophrenia.
@nl
P1476
Animal models for the negative symptoms of schizophrenia.
@en
P2093
Ellenbroek BA
P304
P356
10.1097/00008877-200006000-00006
P577
2000-06-01T00:00:00Z